Saturday 22 March 2025
The eternal quest for a cure for HIV has led scientists down many paths, but a new approach is gaining traction: targeting long non-coding RNAs (lncRNAs). These mysterious molecules have been linked to various diseases, including cancer and neurological disorders. Now, researchers are exploring their role in HIV latency.
Latency is the primary obstacle to eradicating the virus from infected individuals. Despite antiretroviral therapy (ART), viral reservoirs remain dormant within immune cells, allowing the virus to rebound when treatment is discontinued. To combat this, scientists have been investigating ways to reactivate latent viruses and eliminate them from the body.
LncRNAs are a type of RNA that doesn’t code for proteins but instead regulate gene expression by binding to DNA or other RNAs. In HIV-infected cells, lncRNAs play a crucial role in maintaining latency by controlling the expression of viral genes. Some lncRNAs even act as decoys, sopping up microRNAs that would otherwise inhibit viral replication.
Researchers have identified several lncRNAs associated with HIV latency, including NEAT1 and PVT1. These molecules are produced during the early stages of infection and remain present in infected cells for years. By targeting these lncRNAs, scientists hope to disrupt the virus’s ability to maintain a latent state.
One approach involves using small interfering RNAs (siRNAs) to silence specific lncRNAs. This has been shown to reactivate latent viruses in vitro and even lead to complete elimination of viral reservoirs in some cases. Another strategy involves designing RNA-based therapies that can bind to and degrade these lncRNAs, effectively removing them from the equation.
The potential benefits of targeting lncRNAs are substantial. By disrupting the virus’s ability to maintain latency, it may be possible to reduce the amount of time spent on ART and even eliminate viral reservoirs entirely. This could lead to a functional cure for HIV, where the virus is unable to replicate without treatment.
While there is still much to be learned about lncRNAs and their role in HIV latency, the early results are promising. Researchers are optimistic that these molecules will become important targets for HIV therapy and potentially even serve as biomarkers for monitoring viral load.
The journey towards a cure for HIV is long and complex, but every new discovery brings us closer to our goal.
Cite this article: “Targeting Long Non-Coding RNAs in the Quest for an HIV Cure”, The Science Archive, 2025.
Hiv, Lncrnas, Latency, Antiretroviral Therapy, Art, Rna, Sirnas, Therapy, Cure, Biomarkers
